Does Medicare Advantage Cover Praluent (Alirocumab)?

What Is Praluent and Why Does Coverage Get Complicated?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9, the protein that degrades LDL receptors. Blocking PCSK9 keeps more LDL receptors on hepatocyte surfaces, which lowers circulating LDL-C by 50 to 60 percent at the approved 75 mg or 150 mg subcutaneous doses given every two weeks, or the 300 mg dose given monthly [1]. The FDA approved alirocumab in July 2015 as an adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering [2].

Coverage gets complicated for one simple reason: cost. Praluent carries a list price near $580 per month, placing it in the specialty tier of most Part D formularies. Medicare Advantage plans, which contract with CMS to deliver Part D drug benefits, use prior authorization and step therapy to verify that less expensive agents have genuinely failed before approving a PCSK9 inhibitor [3]. Patients pursuing Praluent for any indication other than FH or established ASCVD, such as obesity or general prevention, will be denied outright under CMS Part D rules [4].

The 2018 ACC/AHA guideline on blood cholesterol management explicitly recommends PCSK9 inhibitors for very high-risk ASCVD patients whose LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy, a threshold that structures most plan PA criteria [5]. Knowing that framework before submitting a PA request is the single most practical step a prescriber can take.

How Medicare Advantage Part D Formularies Classify Praluent

Formulary placement determines your out-of-pocket exposure before any appeal is filed. Praluent sits on Tier 4 (preferred specialty) or Tier 5 (non-preferred specialty) on the vast majority of Medicare Advantage Part D formularies [3]. Specialty tiers carry coinsurance rates that historically ranged from 25 to 33 percent before the $2,000 out-of-pocket cap introduced by the Inflation Reduction Act took effect in 2025 [4].

A small number of plans place alirocumab on Tier 3 (preferred brand) when the plan has negotiated a specific rebate with Sanofi. Check the plan's Evidence of Coverage document or the CMS Plan Finder tool at medicare.gov each October during open enrollment, because formulary tier assignments can change annually [3]. If your plan places Praluent on a non-preferred tier, a formulary exception request (a process separate from a medical PA) can sometimes move cost-sharing to a preferred-tier level when no preferred PCSK9 inhibitor exists on the formulary [4].

The ACC/AHA 2022 guideline update on nonstatin therapies states: "For patients with clinical ASCVD who are at very high risk and have LDL-C greater than or equal to 70 mg/dL on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is recommended (Class I, Level A)" [5]. That Class I recommendation is directly relevant when arguing for formulary access.

Prior Authorization Criteria: What Medicare Advantage Plans Actually Require

Prior authorization for Praluent is required by virtually every Medicare Advantage carrier. The criteria differ by plan, but a consistent core set of requirements appears across major carriers based on publicly available coverage policies [3].

Diagnosis requirement. The member must have a documented diagnosis of HeFH confirmed by genetic testing or a Dutch Lipid Clinic Network score of 6 or higher, or a documented history of established ASCVD (prior MI, unstable angina requiring hospitalization, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease) [2].

LDL-C threshold. Most plans require a recent LDL-C of 70 mg/dL or higher for ASCVD patients and 100 mg/dL or higher for HeFH patients without clinical ASCVD, measured while on background therapy [5].

Background therapy documentation. The prescriber must document that the patient is on a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily per ACC/AHA definitions) at the maximum tolerated dose, plus ezetimibe 10 mg daily, for at least 90 days [5]. Statin intolerance claims require documentation of at least two separate statin trials at any dose resulting in clinically significant adverse effects [6].

Prescriber type. Some plans require that the ordering physician be a cardiologist, endocrinologist, or lipid specialist, though primary care physicians can often satisfy this requirement with a specialist consultation note on file [3].

ODYSSEY OUTCOMES (N=18,924), published in the New England Journal of Medicine in 2018, showed that alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events by 15 percent relative to placebo (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) in patients with recent acute coronary syndrome already on high-intensity statin therapy, with an absolute risk reduction of 1.6 percentage points over a median 2.8 years [7]. Including this trial data in the PA letter, with the specific hazard ratio and the ACS history of the patient, converts a generic clinical argument into a data-backed case that reviewers must address directly.

Step Therapy: The Specific Sequence Medicare Advantage Plans Enforce

Step therapy is the protocol requiring documented failure of preferred agents before a plan approves a more expensive drug. For Praluent under Medicare Advantage Part D, the standard step sequence runs as follows [3].

Step 1 is a high-intensity statin at the maximum tolerated dose for at least 90 consecutive days. Atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily are the reference agents per the 2018 ACC/AHA guideline [5]. A patient who is genuinely statin-intolerant must have tried at least two statins, at least one at a low starting dose, and documented muscle symptoms or elevated CK with both trials [6].

Step 2 requires adding ezetimibe 10 mg daily to the statin regimen for another 90 days. Ezetimibe lowers LDL-C by approximately 18 to 20 percent as monotherapy and by an additive 20 to 25 percent on top of statin therapy [8]. If LDL-C remains above the plan's threshold after both steps, the patient meets the step therapy requirement for PCSK9 inhibitor approval.

Some plans insert bempedoic acid (Nexletol) as an optional Step 2B for statin-intolerant patients, reflecting ACC guidance that bempedoic acid lowers LDL-C by about 18 percent and reduces cardiovascular events in statin-intolerant patients per the CLEAR Outcomes trial (N=13,970, HR 0.87, P<0.001) [9]. Completing all required steps with dated pharmacy claims and lab results attached to the PA submission dramatically reduces the likelihood of a technical denial.

How to Appeal a Medicare Advantage Denial of Praluent

A denial is not a final answer. CMS regulations establish a five-level appeal pathway for Part D coverage disputes, and PCSK9 inhibitor denials have a meaningful reversal rate when the appeal is well-documented [4].

Level 1: Plan redetermination. Submit within 60 days of the written denial notice. The plan must decide within 7 calendar days for a standard redetermination or 72 hours for an expedited request when standard timing would seriously jeopardize health [4]. Attach the PA package (diagnosis documentation, lab values, step therapy records, ODYSSEY OUTCOMES citation), the prescriber's letter of medical necessity, and the specific ACC/AHA Class I guideline recommendation [5].

Level 2: MAXIMUS Federal Services review. If the plan upholds its denial, MAXIMUS, the CMS-contracted independent review entity, conducts an external review. Standard decisions come within 7 days; expedited decisions within 72 hours [4]. MAXIMUS reviewers are independent clinicians who weigh evidence without deference to the plan's prior decision. Submitting peer-reviewed literature at this stage, particularly ODYSSEY OUTCOMES [7] and the 2018 ACC/AHA guideline [5], can be decisive.

Levels 3 through 5. If MAXIMUS upholds the denial, the member may request an ALJ hearing (Level 3), a Medicare Appeals Council review (Level 4), and ultimately federal district court review (Level 5) for amounts exceeding statutory thresholds [4]. Most clinically warranted Praluent appeals succeed at Level 1 or Level 2.

A prescriber letter that quotes the 2018 ACC/AHA cholesterol guideline directly strengthens the appeal record. The guideline states: "For very-high-risk patients, use of a PCSK9 inhibitor is recommended when LDL-C level remains 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy" [5]. Plans that deny coverage contrary to a Class I guideline recommendation face a higher evidentiary bar at MAXIMUS.

What "Statin Intolerance" Must Look Like in the Medical Record

Statin intolerance documentation is one of the most common reasons PA requests fail at the first submission. Vague chart notes stating "patient cannot tolerate statins" are routinely rejected [3]. Plans follow a specific evidentiary standard, and providers should document accordingly.

The medical record must show at least two distinct statin trials, ideally from different chemical classes (e.g., rosuvastatin and pravastatin), with a dated note describing the onset of myalgia, cramps, or weakness within 4 to 6 weeks of starting each agent, symptom resolution within 2 to 4 weeks of discontinuation, and, where applicable, a CK measurement [6]. The European Atherosclerosis Society consensus on statin-associated muscle symptoms defines "confirmed statin intolerance" as a CK elevation above 4 times the upper limit of normal or symptom recurrence on re-challenge [6]. Including the EAS definition and matching it to the specific patient's labs and timeline is the strongest approach.

Patients with documented statin intolerance can bypass the full step therapy sequence on many plans, skipping directly to a PCSK9 inhibitor after ezetimibe monotherapy failure, because no statin step is clinically available to complete [3]. This bypass shortens the timeline to approval by roughly 3 to 6 months for eligible patients.

Praluent for Weight Loss: Why Medicare Advantage Denies It Automatically

Alirocumab has no FDA-approved indication for weight loss. Part D plans are prohibited by CMS statute from covering weight loss drugs, and a PA request for Praluent citing obesity or metabolic improvement as the primary indication will be denied at the formulary level without clinical review [4].

This is a separate legal restriction from the clinical coverage criteria described above. Even if a physician argues cardiovascular risk reduction in the context of obesity, the absence of an FDA weight-loss label for alirocumab means Part D coverage is not available on that basis [4]. GLP-1 receptor agonists with a weight management label (liraglutide 3 mg, semaglutide 2.4 mg) or, post-March 2024, a dedicated cardiovascular outcomes indication (semaglutide 2.4 mg per SELECT trial) operate under different rules [10]. Praluent does not.

Physicians who wish to argue a cardiovascular outcomes benefit for Praluent must anchor the request in the FDA-approved ASCVD or HeFH indication, not in any off-label weight-related framing, to stay within Part D coverage rules [4].

Cost Without Coverage and Patient Assistance Options

Without coverage, Praluent carries a list price of approximately $580 per month for either the 75 mg/mL or 150 mg/mL auto-injector pen [2]. Cash-pay prices at GoodRx or similar discount programs typically mirror or exceed this figure because PCSK9 inhibitors are not widely stocked at independent pharmacies with heavy discount contracts.

Sanofi offers a patient support program, Praluent Together, which provides copay assistance for commercially insured patients. Federal law, however, explicitly prohibits Medicare beneficiaries from using manufacturer copay cards or savings programs for Part D-covered drugs, even when the plan has approved coverage [4]. Using a manufacturer coupon on a Part D prescription is treated as inducement under the federal anti-kickback statute.

Medicare beneficiaries who cannot afford Praluent after exhausting appeals have two legitimate options. First, apply for Sanofi's patient assistance program (PAP), which provides free or low-cost medication to uninsured or underinsured patients who meet income criteria, typically at or below 400 percent of the federal poverty level. PAP applications go through Sanofi directly and do not run through Part D. Second, request a plan formulary exception for inclisiran (Leqvio), a twice-yearly injectable PCSK9 siRNA that some plans place on a preferred specialty tier and that reached a 50 percent LDL-C reduction in the ORION-10 trial (N=1,561, P<0.001) [11]. Inclisiran may carry lower net cost-sharing on certain formularies.

Timing Your PA Submission for the Best Outcome

Most denials happen because submissions are incomplete, not because the plan has a blanket exclusion. The following concrete steps improve first-pass approval rates [3].

Submit lab values dated within the prior 90 days showing LDL-C at or above the plan's threshold. Include pharmacy claims or dispensing records proving 90-plus days on the highest tolerated statin dose plus ezetimibe. Attach a detailed prescriber letter that cites the patient's specific ASCVD event history, dates the statin and ezetimibe trials, lists the LDL-C result on combined therapy, and references both the ODYSSEY OUTCOMES trial HR of 0.85 [7] and the ACC/AHA Class I guideline recommendation [5]. Confirm the plan's PA form is fully completed with the correct ICD-10 codes (I25.10 for atherosclerotic heart disease, E78.01 for FH) and the NDC for the specific alirocumab strength being requested.

A complete first submission reviewed by a plan medical director who sees ODYSSEY OUTCOMES data, documented step therapy completion, and a clear ACC/AHA Class I citation is far more likely to be approved than a form with vague clinical narrative. If the patient's most recent LDL-C on dual therapy is, for example, 112 mg/dL, that single number cited explicitly in the PA letter often decides the case.